Business Description
![Nurix Therapeutics Inc Nurix Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BVCC.png?14)
Nurix Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US67080M1036
Share Class Description:
NRIX: Ordinary SharesDescription
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.37 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.01 | |||||
Beneish M-Score | -3.14 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.6 | |||||
3-Year EBITDA Growth Rate | 13.4 | |||||
3-Year EPS without NRI Growth Rate | 1.3 | |||||
3-Year FCF Growth Rate | -77.4 | |||||
3-Year Book Growth Rate | -18 | |||||
Future 3-5Y Total Revenue Growth Rate | 1.89 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 71.39 | |||||
9-Day RSI | 70.59 | |||||
14-Day RSI | 68.32 | |||||
6-1 Month Momentum % | 55.59 | |||||
12-1 Month Momentum % | 55.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.86 | |||||
Cash Ratio | 2.78 | |||||
Days Sales Outstanding | 9.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.8 | |||||
Shareholder Yield % | -0.53 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -194.51 | |||||
Net Margin % | -178.93 | |||||
FCF Margin % | -103.69 | |||||
ROE % | -63.65 | |||||
ROA % | -42.64 | |||||
ROIC % | -129.39 | |||||
ROC (Joel Greenblatt) % | -442.44 | |||||
ROCE % | -59.41 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.87 | |||||
PB Ratio | 6.08 | |||||
Price-to-Tangible-Book | 6.08 | |||||
EV-to-EBIT | -6.68 | |||||
EV-to-EBITDA | -7.36 | |||||
EV-to-Revenue | 13 | |||||
EV-to-Forward-Revenue | 13.73 | |||||
EV-to-FCF | -12.54 | |||||
Price-to-Net-Current-Asset-Value | 9.57 | |||||
Price-to-Net-Cash | 10.23 | |||||
Earnings Yield (Greenblatt) % | -14.97 | |||||
FCF Yield % | -6.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nurix Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 80.887 | ||
EPS (TTM) ($) | -2.66 | ||
Beta | 2.05 | ||
Volatility % | 105.74 | ||
14-Day RSI | 68.32 | ||
14-Day ATR ($) | 1.378045 | ||
20-Day SMA ($) | 17.5555 | ||
12-1 Month Momentum % | 55.75 | ||
52-Week Range ($) | 4.22 - 22.4388 | ||
Shares Outstanding (Mil) | 61.07 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nurix Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nurix Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nurix Therapeutics Inc Frequently Asked Questions
What is Nurix Therapeutics Inc(NRIX)'s stock price today?
The current price of NRIX is $20.87. The 52 week high of NRIX is $22.44 and 52 week low is $4.22.
When is next earnings date of Nurix Therapeutics Inc(NRIX)?
The next earnings date of Nurix Therapeutics Inc(NRIX) is 2024-07-12 Est..
Does Nurix Therapeutics Inc(NRIX) pay dividends? If so, how much?
Nurix Therapeutics Inc(NRIX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |